NAC Supplementation May Reduce Risks for Preterm Babies, Study Finds

A new study suggests that antenatal N-acetylcysteine (NAC) supplementation could help reduce complications in babies born preterm. The research focused on pregnant women at risk of early delivery and found promising results. NAC, a well-known antioxidant, appears to offer protective benefits during pregnancy without harming fetal development. Preterm birth, defined as delivery before 37 weeks, often leads to long-term health issues for infants. Researchers explored whether NAC—a glutathione precursor that combats oxidative stress—could lower these risks. The study revealed a clear reduction in acute neonatal complications among babies whose mothers received NAC.

NAC works by boosting the body’s ability to neutralise harmful free radicals and reducing inflammation. Importantly, the treatment did not shorten gestation periods or interfere with fetal growth, confirming its safety. However, the effectiveness of NAC depends on precise timing and dosage, which require further investigation. The findings highlight potential for NAC to ease the global healthcare burden tied to preterm births. By cutting disability rates and medical costs, the supplement could become a valuable tool in maternal-fetal medicine. Still, experts stress the need for larger, multi-centre trials to confirm these results across different populations.

The study marks a step forward in preventing preterm birth complications through NAC supplementation. If validated in broader trials, this approach could improve outcomes for at-risk pregnancies. Further research will determine the best ways to apply these findings in clinical practice.